Aurinia Pharmaceuticals Inc. (AUPH) is a Healthcare stock trading at $16.49 (as of 2026-06-18), with a market capitalization of $2.02B and a trailing P/E of 7.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company developing and commercializing therapies for diseases with unmet medical need in the United States and internationally. Its product portfolio includes LUPKYNIS for adult patients with active lupus nephritis, and it also has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.